Lung Cancer Management

Scope & Guideline

Transforming Knowledge into Practice for Lung Cancer

Introduction

Delve into the academic richness of Lung Cancer Management with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1758-1966
PublisherFUTURE MEDICINE LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Converge2014, from 2020 to 2024
AbbreviationLUNG CANCER MANAG / Lung Cancer Manag.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressUNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND

Aims and Scopes

The journal 'Lung Cancer Management' primarily focuses on advancing the understanding and treatment of lung cancer through a multidisciplinary approach. It encompasses various aspects of lung cancer management, including diagnosis, treatment, patient care, and health economics.
  1. Clinical Management of Lung Cancer:
    The journal emphasizes research related to the diagnosis and treatment of lung cancer, including novel therapies, chemotherapy, and immunotherapy. It aims to provide insights into the best clinical practices for managing different types of lung cancer.
  2. Health Economics and Cost Analysis:
    Research on the economic implications of lung cancer diagnosis and treatment is a core focus. This includes studies on cost differences between healthcare systems and the financial burden of lung cancer on patients and healthcare providers.
  3. Biomarkers and Genetic Research:
    The journal highlights studies that explore the role of biomarkers and genetic mutations in lung cancer, particularly in relation to targeted therapies and personalized medicine.
  4. Patient Quality of Life and Supportive Care:
    A significant area of focus is on the quality of life for lung cancer patients, including studies on symptom management, psychological support, and the impact of lung cancer on daily living.
  5. Public Health and Screening Initiatives:
    The journal also addresses public health issues, such as disparities in lung cancer screening and the implementation of screening programs to improve early detection.
Recent publications in 'Lung Cancer Management' indicate a clear shift towards certain emerging themes that are gaining traction. These themes reflect current challenges and advancements in lung cancer research and treatment.
  1. Precision Medicine and Targeted Therapies:
    There is an increasing focus on precision medicine, particularly studies evaluating the efficacy of targeted therapies for specific genetic mutations in lung cancer, such as ALK and EGFR. This trend signifies a move towards more personalized treatment plans.
  2. Impact of COVID-19 on Lung Cancer Care:
    Research examining the implications of the COVID-19 pandemic on lung cancer diagnosis and treatment has emerged as a significant theme, highlighting challenges in patient care during global health crises.
  3. Real-World Evidence and Outcome Studies:
    There is a growing emphasis on real-world evidence and outcomes in lung cancer treatment, focusing on the effectiveness of therapies in diverse populations and settings, which is crucial for informing clinical guidelines.
  4. Quality of Life and Patient-Centered Care:
    Studies addressing the quality of life for lung cancer patients and their psychological well-being are gaining more attention, emphasizing the importance of holistic care in cancer management.
  5. Health Disparities and Screening Initiatives:
    Research focused on health disparities among different populations and the effectiveness of lung cancer screening initiatives is increasingly prevalent, reflecting a commitment to improving access and outcomes in lung cancer care.

Declining or Waning

As the field of lung cancer management evolves, some themes have gradually lost prominence in recent publications. This reflects a shift towards more contemporary issues and methodologies in lung cancer research.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decrease in research focused on traditional chemotherapy methods, with more emphasis now placed on targeted therapies and immunotherapy. This reflects the evolving treatment landscape and the growing preference for personalized medicine.
  2. Basic Science Research:
    Research that focuses purely on basic science aspects of lung cancer, such as cell biology or preclinical studies, appears to be waning. The journal is increasingly prioritizing clinical outcomes and real-world evidence.
  3. Generalized Treatment Protocols:
    Studies that discuss generalized treatment protocols without incorporating specific patient demographics or genetic profiles are less frequently published. The trend is moving towards more tailored approaches that consider individual patient characteristics.

Similar Journals

Clinical Genitourinary Cancer

Empowering professionals with cutting-edge findings.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Eurasian Journal of Medicine and Oncology

Advancing the Frontiers of Medicine and Oncology
Publisher: KARE PUBLISSN: Frequency: 4 issues/year

Eurasian Journal of Medicine and Oncology is a premier international journal established by KARE PUBL, dedicated to the exploration and advancement of knowledge within the fields of Internal Medicine and Oncology. Published in Turkey, this periodical offers a unique platform for researchers, healthcare professionals, and students to disseminate innovative research findings and clinical insights. With a commendable impact reflected in its 2023 Scopus rankings—ranking #49 in Internal Medicine and #143 in Oncology—this journal occupies a vital role in the academic and professional dialogue surrounding contemporary medical challenges. Operating under an Open Access framework, the journal facilitates broad dissemination of knowledge, ensuring that significant research is accessible to a global audience. The ongoing convergence of research and clinical application from 2019 to 2024 positions the Eurasian Journal of Medicine and Oncology as an essential resource for those committed to advancing the frontiers of medicine and oncology in an increasingly interconnected world.

Pulmonary Medicine

Unveiling Breakthroughs in Lung Health
Publisher: HINDAWI LTDISSN: 2090-1836Frequency: 1 issue/year

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Pulmonology

Leading the way in open-access research for respiratory disorders.
Publisher: ELSEVIERISSN: 2531-0437Frequency: 6 issues/year

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Canadian Journal of Respiratory Critical Care and Sleep Medicine

Shaping the future of respiratory and critical care medicine.
Publisher: TAYLOR & FRANCIS INCISSN: 2474-5332Frequency: 4 issues/year

Welcome to the Canadian Journal of Respiratory Critical Care and Sleep Medicine, a prestigious peer-reviewed journal published by Taylor & Francis Inc. With an ISSN of 2474-5332 and an E-ISSN of 2474-5340, this journal serves as a vital platform for disseminating cutting-edge research in the fields of critical care, intensive care medicine, and pulmonary and respiratory medicine. Since its inception in 2017, the journal has established itself within the academic community, currently holding a Q2 ranking in Critical Care and Intensive Care Medicine and a Q3 ranking in Pulmonary and Respiratory Medicine for 2023. Although it operates under a standard access model, the journal remains committed to providing valuable insights and advancing knowledge through rigorous research articles, reviews, and case studies. Positioned in the heart of the United States, the journal aims to foster collaboration and innovation among healthcare professionals, researchers, and students dedicated to enhancing respiratory care and critical treatment protocols. Join us in exploring the dynamic intersection of research and practice that defines our mission.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Exploring groundbreaking discoveries in cancer treatment.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

CHEMOTHERAPY

Shaping the Future of Pharmacological Sciences
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Zeitschrift fur Pneumologie

Pioneering Discoveries in Respiratory Medicine
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Molecular and Clinical Oncology

Empowering breakthroughs in cancer biology and treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Clinical Lung Cancer

Leading the way in comprehensive lung cancer exploration.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.